Oral BPC-157 Dosage — What Studies Used

The majority of research done on BPC-157 has used injections to deliver the substance. However, there are a few studies that did look at the oral delivery of the peptide. On this page, we have compiled some of the oral delivery research done so far, including the doses being tested in the studies.

Oral BPC-157 Dosage - What Animal Studies Administered

The use of BPC-157 as an oral medication is most observed in studies of gastrointestinal protection. The question remains whether the peptide ingested into the stomach can have any local and/or systemic effect. In rats, the answer is conditional yes.

Gavage Doses in Rat Gastrointestinal Models

Gavage refers to the process of inserting a tube into the stomach to administer substances without the chewing and involuntary swallowing process. This is the method that researchers use more often when it comes to researching peptides in rodents because it helps with exact measurement of doses and volumes.

Sikiric and his partners (1999) administered BPC-157 at 10 mcg/kg of body weight through intragastric gavage to rats in a rat gastric cytoprotection model. The same research team tested a significantly lower quantity of 10 ng/kg by the same means. Both of these doses had a protective effect against ethanol-induced stomach lesions in the animals studied (PMID 9920181). In another research done earlier, Sikiric and his collaborators (1993) also used the oral route along with the intraperitoneal application of the drug in anti-ulcer studies in rats with multiple dose levels (PMID 8298609).

It is important to clarify what gavage does and does not simulate. While it delivers food directly to the stomach, it does not replicate the act of swallowing a capsule, which involves the role of saliva, the time taken for passage through the esophagus, and the variable rates at which food gets released from the stomach.

Drinking-Water Administration in Mouse Studies

Protocols existed in which BPC-157 was administered to animals via drinking water, so providing ad libitum access to the compound. While this method is not as accurate because water consumption varies between individuals, it provides a more authentic oral exposure pattern. The work by Sikiric and colleagues (2018) was able to compile and analyze many studies using this method of administration and noted that the BPC-157 treatment via drinking water at doses of approximately 10 mcg/kg and 10 ng/kg had a significant effect in various models of rats and mice (PMID 29879879).

The concentration of peptide in drinking water was determined based on average daily water intake and weight of the organism. This is not a method that is easily translated to the human dose calculation process.

Oral vs Parenteral BPC-157 in Research

Bioavailability Differences Observed in Rodents

A number of studies have compared both oral and injectable delivery methods at the same time, and both methods were shown to lead to some results for the measured endpoints, although the magnitude sometimes differed.

There has been no official bioavailability study conducted with plasma concentration measurements for BPC-157 in any species. The peptide has shown beneficial effects in studies with oral administration in rats, but it is unknown what percentage of the substance entered the systemic circulation and how much acted locally in the intestines.

Why Oral Data Cannot Set a Human Capsule Dose

Three barriers hinder the drawing parallels between rodent dosage recommendations and those for humans. The first barrier is related to significant differences in various parameters including gastric pH, enzyme profiles, and transit times in rats and humans. The second barrier is the total absence of pharmacokinetic data on BPC-157 in various species so the rate of absorption cannot be specified. The last barrier is that the stability of the peptide in capsules kept at room temperature can differ significantly from that of the peptide administered immediately from the solution by gavage.

These are not minor technical details. They are foundational unknowns.

BPC-157 Capsule Products - What Vendors Sell

Capsule Sizes on the Market vs Study Amounts

Standard capsule products have either 250 mcg or 500 mcg of BPC-157 per capsule. A few vendors sell capsules containing 750 mcg or even 1000 mcg of BPC-157. The values for these amounts were not obtained from any published dose-response studies conducted on humans since there aren't any.

To put the numbers in perspective: a 10 mcg/kg dose for a 250-gram rat equals 2.5 mcg total. A 500 mcg capsule marketed for human use contains 200 times that absolute amount. Whether allometric scaling justifies that difference is debatable, and the debate itself is academic because no controlled human data anchor it. Our reconstitution calculator can help with concentration math for liquid preparations, though it does not resolve the fundamental dosing question for oral use.

What the Oral Data Does Not Establish

No Dose-Response Curve in Humans

The term dose-response curve refers to the relationship between dosage of the substance and the extent of its effect. Humans appear not to have a clear dose-response curve for taking BPC-157 orally. Animals tested showed weak evidence of such a curve. Most studies have administered one or two doses of this compound and reported only binary outcomes (presence of a lesion or absence of it; overlapping of peptide treatment in the healing process or its absence). At this time, it is quite apparent that no thorough studies exists in all investigated species to determine the threshold and effectiveness of oral doses of the peptide.

Stability and Absorption Questions Still Open

BPC-157 is a peptide made up of 15 amino acids. Generally speaking, peptides of this size are vulnerable to breakdown by enzymes in the digestive tract. The observation that orally administered BPC-157 exhibited effects in rat studies raises the issue of whether it acts locally in the gut lining or whether it may be active in fragmented form or whether this specific sequence of peptide has some unusual protease stability. Existing literature fails to clarify these questions.

Capsule formulation presents new factors that can be cautiously examined. The effect of enteric coating, filler materials, and storage conditions on the stability of peptides should be investigated. There are no studies available on the stability and efficacy of peptides using commercial BPC-157 capsules.